News from csl A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 30, 2014, 11:26 ET
CSL Behring logo. (PRNewsFoto/CSL Behring)

Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant

A study presented at the 2014 World Transplant Congress evaluated the safety and efficacy of CSL Behring's C1 Inhibitor (C1-INH) concentrate in...

Jul 14, 2014, 09:00 ET

CSL Behring meldet die Zulassung der auf drei Jahre erweiterten Haltbarkeit von Beriate® in Deutschland

CSL Behring gab heute bekannt, dass das Paul-Ehrlich-Institut in Deutschland die Erweiterung der Haltbarkeit von Beriate® 250/500/1000/2000,...

Jun 24, 2014, 11:43 ET

CSL Behring maakt winnaar van de 2014 Interlaken Leadership Awards bekend

-- Interlaken Leadership Awards-programma ondersteunt origineel neuro-immunologisch onderzoek  CSL Behring kondigde vandaag...

Jun 24, 2014, 09:00 ET

CSL Behring Announces the 2014 Interlaken Leadership Awards Recipient

 CSL Behring announced today that Bart C. Jacobs, M.D., Ph.D., Erasmus University Medical Center, Rotterdam, Netherlands, is the recipient of...

May 20, 2014, 09:00 ET
CSL Behring logo.  (PRNewsFoto/CSL Behring)

CSL Behring Launches Hizentra® Co-Pay Relief Program

 People managing primary immunodeficiency (PI) with CSL Behring's Hizentra® (Immune Globulin Subcutaneous [Human]) may now be eligible for...

May 14, 2014, 08:30 ET

CSL Behring Proudly Supports HAE Day with Global Partnerships, Donations and Hereditary Angioedema Awareness Events

 As a Diamond Sponsor of HAE Day on May 16, 2014, CSL Behring is proud to continue its partnership with HAEi, the International Patient...

May 11, 2014, 19:15 ET

New Findings Support Less Frequent Dosing in Hemophilia B Patients Treated with Coagulation Factor IX with Recombinant Albumin (rIX-FP)

Interim Phase II/III and III findings presented today by CSL Behring at the World Federation of Hemophilia (WFH) 2014 Congress demonstrate an...

May 09, 2014, 09:30 ET
CSL Behring's new biotechnology manufacturing facility in Melbourne, Australia. It is one of the largest and most advanced facilities of its kind in the world and will produce novel recombinant therapies on a large scale for international clinical trials. (PRNewsFoto/CSL Behring)

CSL Opens World-Class, Advanced Manufacturing Facility for Late-Stage Production of Hemophilia Therapies Now in Development

 CSL Limited (ASX:CSL), parent company of CSL Behring which is based in King of Prussia, PA, today opened the CSL Behring Biotechnology...

May 02, 2014, 12:07 ET
May 02, 2014, 11:55 ET
May 02, 2014, 09:49 ET

CSL Behring recluta a su primer paciente en el ensayo pivote en fase III del factor recombinante VIII de cadena única

- CSL Behring recluta a su primer paciente en el ensayo pivote pediátrico mundial en fase III del factor recombinante VIII de cadena...

May 02, 2014, 08:30 ET

CSL Behring enrolls first patient in global pediatric Phase III pivotal study of recombinant factor VIII single chain (rVIII-SingleChain) to treat severe hemophilia A

 CSL Behring today announced that the first patient has been enrolled in the pivotal pediatric phase III study to evaluate the efficacy, safety...

Apr 17, 2014, 08:30 ET

CSL Behring Continues Commitment to Donate Bleeding Disorder Medications to World Federation of Hemophilia

 CSL Behring announced today that the company will continue its ongoing commitment to the global coagulation disorders...

Mar 25, 2014, 12:00 ET

CSL Behring Launches My Access™ Cost Share Program during Hemophilia Awareness Month

 People who are treating hemophilia A or von Willebrand Disease (VWD) with a CSL Behring therapy may now be eligible for financial support...

Mar 24, 2014, 10:00 ET
CSL Behring logo. (PRNewsFoto/CSL Behring)

Patient Advocates And Social Workers Will Be Trained On Intricacies Of Affordable Care Act With CSL Behring Grant

 Navigating the complexities of the Affordable Healthcare Act (ACA) can be challenging, particularly where patients with chronic medical...

Mar 01, 2014, 12:45 ET

Patient Satisfaction and Convenience Increased with Current Hereditary Angioedema Treatment Options, According to Study Findings

 Findings announced by CSL Behring today show that current hereditary angioedema (HAE) treatment options, such as C1 Esterase Inhibitor...

Feb 20, 2014, 08:30 ET

First patient enrolled in phase III of COMPACT, a study of volume-reduced subcutaneous C1-INH for prevention of Hereditary Angioedema (HAE) attacks

CSL Behring today announced it has enrolled the first patient in COMPACT, an international phase III study of a volume-reduced, subcutaneous...

Feb 20, 2014, 08:30 ET
CSL Behring logo. (PRNewsFoto/CSL Behring)

CSL Behring and CSL Plasma Employees Open Their Hearts to Those in Need

 You can tell a lot about a company and its employees by the way they give back to the community. CSL Behring, its subsidiary, CSL Plasma and...

Dec 13, 2013, 17:58 ET
CSL Behring logo.  (PRNewsFoto/CSL Behring)

Kcentra®, from CSL Behring, Receives FDA Approval for Use in Warfarin Reversal in Patients Undergoing Surgery

CSL Behring today announced that Kcentra® (Prothrombin Complex Concentrate [Human]) has received U.S. Food and Drug Administration (FDA)...

Dec 09, 2013, 19:00 ET
CSL Behring logo.  (PRNewsFoto/CSL Behring)

CSL Behring Study Shows Kcentra® Superior to Plasma for Warfarin Reversal in Patients Requiring an Urgent Surgical Procedure

Data presented today by CSL Behring at the 55th Annual Meeting of the American Society of Hematology (ASH) showed Kcentra® (Prothrombin...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge